Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) - Peters, S; Gettinger, S; Johnson, M L (J Clin Oncol, 2017)
et al.